Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Portfolio Pulse from Benzinga Newsdesk
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), has submitted a grant application to the National Institute of Allergy and Infectious Diseases (NIAID) for funding to support its Phase I study of NP-300, a novel drug candidate for the treatment of moderate-to-severe diarrhea, including cholera.
September 12, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's subsidiary, Napo Pharmaceuticals, has applied for a grant to fund its Phase I study of NP-300. This could potentially boost Jaguar Health's portfolio if the grant is approved and the drug proves successful.
The news directly pertains to Jaguar Health as Napo Pharmaceuticals is a subsidiary of the company. If the grant is approved and the drug proves successful in its Phase I study, it could potentially add a significant asset to Jaguar Health's portfolio, which could positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100